Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

abolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States, subject to FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the termination of Arena's collaboration with Ortho-McNeil-Janssen and related expectations and future activities; the therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of APD597 alone and in combination; the potential of GPR119; Arena's GPR119 patent portfolio and program and potential opportunities; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the risk that APD597 or GPR119 agonists as a class may not realize their potential or ever receive marketing approval; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner and/or the information
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Ameritox, the nation,s leader in pain medication monitoring, ... become part of its Urine Drug Monitoring (UDM) ... improve the clinical outcomes for injured workers. ... in the workers, compensation industry, has used UDM ... strategy for several years. By establishing a comprehensive ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
Breaking Medicine Technology:Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
(Date:5/23/2013)... May 23, 2013 Dr. Damon Huffman of ... suffer from gum disease a revolutionary new treatment method with ... millions of Americans who suffer from periodontal disease, and many ... treatment. Dr. Huffman is hoping that LANAP will encourage ... treatment. , Periodontal disease can cause gums ...
(Date:5/23/2013)... Vinci surgical robot maker Intuitive Surgical defeated negligent training ... according to Bloomberg.* The Rottenstein Law Group LLP, which ... disappointment in the ruling but encourages those looking to ... verdict as representative of all da Vinci lawsuits. , ... Surgical Inc.; 09-2-03136-5, Superior Court, Port Orchard, Wash.) focused ...
(Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
Breaking Medicine News(10 mins):Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... The Children,s Hospital of Philadelphia contributed important expertise to ... brain tumor typically found in children. The large multicenter ... holds intriguing clues to gene changes on signaling pathways ... The most common cancerous brain tumor in children, medulloblastoma ...
... , Orange, Calif., Dec.16, 2010 The American Heart Association ... of care for heart failure patients. The Get With ... UC Irvine Medical Center has achieved at least 85 percent ... heart failure patients. The medical center,s compliance rate was ...
... By Dennis Thompson HealthDay Reporter , THURSDAY, ... supplements for centuries to cure all manner of ills and ... the use of such plants as St. John,s wort and ... unknown. But the federal government is spending millions of ...
... a new report that bucks the concerns raised by the ... Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much ... against tobacco-related diseases and death. The review, which ... the Journal of Public Health Policy , is the ...
... treatment of chronic pain from the patient,s perspective, there has ... pain. In a study in the November ... from the Regenstrief Institute, the Indiana University School of Medicine, ... Medical Center report that chronic pain takes a toll on ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... advisers urged the agency to take a new look at ... that include mercury. The FDA had ruled in 2009 ... "We need to see where the science is and ...
Cached Medicine News:Health News:CHOP experts collaborate in gene survey of childhood brain cancer; intriguing clues found 2Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:U.S. Spending Millions to See if Herbs Truly Work 2Health News:U.S. Spending Millions to See if Herbs Truly Work 3Health News:Evidence suggests e-cigs safer than cigarettes, researcher claims 2Health News:It's a pain to take care of pain 2Health News:It's a pain to take care of pain 3Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3
... Varicella-Zoster (VZ) test system ... and semi-quantitative detection of VZ ... by the indirect fluorescent antibody ... determine or confirm a recent ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) ... is intended for the detection ... virus in human serum as ... of primary infection or reactivation. ...
... Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
ELISA kit for Varicella-zoster IgM....
Medicine Products: